ResearchCon 2022 | Trikafta Experiences: Keeping it real-(world)
Автор: Cystic Fibrosis Foundation
Загружено: 2022-04-22
Просмотров: 1429
The approval of Trikafta, a CFTR modulator, was a breakthrough in cystic fibrosis treatment, providing amazing benefits for many people with CF. At the same time, we know that each person’s journey with this treatment is unique, and there is no universal Trikafta experience.
During this session, clinicians and adults with CF will present an honest discussion of what we know about Trikafta and where future research is heading. You’ll hear personal stories that highlight both the good and the challenging; including how hard it can be to determine whether a new symptom is being caused by a drug.
Originally recorded April 9, 2022.
0:00:00 | Trikafta Experiences: Keeping it real-(world)
0:02:58 | Meet Tré LaRosa, an adult with cystic fibrosis who takes Trikafta
0:05:35 | Meet Erin Kunzen, an adult with cystic fibrosis who experienced adverse events while taking Trikafta
0:07:45 | Poll questions – audience demographics
0:13:20 | Trikafta and studies of real-world experience
0:25:37 | What does the future hold for those taking Trikafta?
0:32:28 | Erin’s CF story
0:37:33 | How does Trikafta work? What are the common adverse events?
0:45:12 | Erin’s challenges with Trikafta
1:01:50 | How can you report adverse events on Trikafta?
1:04:57 | Does Trikafta affect the occurrence of kidney stones or eye issues?
1:07:20 | Is there any research looking into Trikafta and mental/neurological effects?
1:11:57 | Closing
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
